WO1989001740A1 - Diet fortification - Google Patents
Diet fortification Download PDFInfo
- Publication number
- WO1989001740A1 WO1989001740A1 PCT/SE1988/000436 SE8800436W WO8901740A1 WO 1989001740 A1 WO1989001740 A1 WO 1989001740A1 SE 8800436 W SE8800436 W SE 8800436W WO 8901740 A1 WO8901740 A1 WO 8901740A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- salts
- accordance
- derivatives
- carnitine
- Prior art date
Links
- 230000037213 diet Effects 0.000 title claims abstract description 9
- 235000005911 diet Nutrition 0.000 title claims abstract description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 210000003205 muscle Anatomy 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 16
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 9
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 8
- 229940088594 vitamin Drugs 0.000 claims abstract description 4
- 229930003231 vitamin Natural products 0.000 claims abstract description 4
- 235000013343 vitamin Nutrition 0.000 claims abstract description 4
- 239000011782 vitamin Substances 0.000 claims abstract description 4
- 235000015097 nutrients Nutrition 0.000 claims abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 3
- 238000012549 training Methods 0.000 claims description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 16
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 14
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 12
- 239000011677 pyridoxine Substances 0.000 claims description 9
- 235000008160 pyridoxine Nutrition 0.000 claims description 9
- 229940011671 vitamin b6 Drugs 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 6
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 150000003227 pyridoxines Chemical class 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 229940110767 coenzyme Q10 Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 37
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000002027 skeletal muscle Anatomy 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- 210000003470 mitochondria Anatomy 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 238000002485 combustion reaction Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000009466 transformation Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000037074 physically active Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000006609 metabolic stress Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical group OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- -1 hydrogen ions Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition intended to constitute a diet fortification for the temporary and/or long-term improvement of the efficiency at muscle work of the individual who takes the diet fortification, and it relates moreover to the application of such a composition.
- a great number of beverages are on the market which are intended to be taken in cases of prolonged physical exertion in order to replace above all the loss of fluid the body has suffered through perspiration. It is a further objective of these beverages to replace the glucose and the salts in blood and muscles which have been consumed and/or lost.
- the beverages therefore, are aqueous solutions containing different carbohydrates.
- the beverages of the type mentioned here are often referred to as sports beverages.
- the transformation of energy in the musculature depends not only on the suppl y of substrate for energy transfer but al so depends on the metabolic preconditions required so that optimum breakdown in the muscle fibres can be achieved. This applies especially to hard and frequently prolonged physical exercize e.g. during training and competitive activity but also in cases of temporary physical strains in skilled work or in other stress situations with pronouned muscular activity (e.g. contractures).
- composition intended primarily for healthy, physically active persons, where the composition is apt to improve the opportunities for training and thus obviously increase the physical exercize capacity.
- the composition is primarily intended for active persons which have reached a very high level of training, such as long-distance runners, boxers, cyclists, swimmers, decathletes and the like. Such a high level can readily be determined by those skilled in the art of sporting using inter alia ergorneter-cycle techniques. Reference is made to literature available within this area (cf. PH Astrand: Ergometri-Konditionsprov, 1962, Folksam Skriftserie).
- the composition includes ingredients which can inactivate certain harmful by-products of the metabolism. The formation of such harmful substances, e.g. free oxygen radicals, are a normal biological phenomenon, and the cell has developed a number of protective mechanisms for this purpose. Examples of these are so-called antioxidants with
- Endurance work is characterized in that large quantities of oxygen (O 2 ) are transported to the musculature for the purpose of being used in the combustion metabolic process, carbon dioxide (CO 2 ) and water (H 2 O) being formed.
- O 2 oxygen
- CO 2 carbon dioxide
- H 2 O water
- a basic requirement for endurance work therefore, is a good supply of oxygen in the muscle fibres.
- the term fitness also refers to the capacity available for taking up and transporting oxygen to the working musculature. This capacity in turn determines:
- symptom-limited working capacity which is determined by the combination: capacity for oxygen transport and. lactic acid tolerance in the working musculature.
- the critical value for lactic acid formation in point 1 that is to say the OBLA-value (Onset of Blood Lactate Accumulation), corresponds to a highest work load for an individual with regard to endurance work.
- the maximum working capacity according to point 2 or the SL-value (Symptom Limited) signifies the "ceiling" of efficiency and provides, inter alia, information as to the maximum lactic acid concentration in muscle and blood.
- Ergometer cycle and graded work that is to say stepwise increase of intensity (20-40 W) per minute are used in the so-called OBLA/SL-test.
- W OBLA and W SL are used, and the unit here is Watt (W).
- Cofactors have different functions in the muscle cell: they activate e.g. the enzymes which participate in the breakdown and transformation of chemically bonded energy to other forms of energy, e.g. mechanical work, via ATP and creatin phosphate. Other substances, which sometimes are summed up under the concept cofactors, also can be effective as "detoxication units" in the metabolism. The body is able to control the formation of oxygen radicals under normal conditions and the formation consequently can be handled and tolerated by the tissue in question.
- the present invention relates to a composition containing substances (cofactors) which contribute to a more effective transformation of energy and "detoxication" in connection with the metabolism.
- the present invention especially relates to a composition primarily intended to be consumed by individuals which have reached a very high level of training, and as a further aspect the invention relates to a method of use of the composition comprising administering an effective amount of the composition for increasing the capacity at muscle work and especially the capacity of such well trained individuals.
- the composition is intended in the first place to be used in conjunction with the supply of energy through the intake of food and/or drink. In certain applications the composition is added, therefore, to the food and/or drink which is to be taken.
- the composition includes as the essential component the coenzyme Q 10 (hereinafter called CoQ 10 ) chemically known as ubiquinone. According to what has been found so far, CoQ 10 has several functions:
- CoQ 10 brings about not only a biochemical but also a purely physical coupling inside the mitochondria between these different functions and functional units. This causes CoQ 10 to be very active in case of an excess of electrons.
- the composition as a rule includes nutrients, salts, vitamins, trace substances, flavourings, aromatics etc, known per se.
- L-carnitine and/or pyridoxine are incorporated into the composition in accordance with an embodiment of the invention.
- salts and/or derivatives of L-carnitine and/or pyridoxine arc included in the composition.
- Carnitine has a key function in the transport of free fatty acids into the mitochondria and in the combustion of fatty acids to carbon dioxide and water. If carnitine, and hence the conveyor of free fatty acids is lacking, these will accumulate intracellularly in even higher concentrations. Free fatty acids have a releasing effect on the mitochondria breathing with a consequent increased radical formation.
- l ⁇ g has not been clearly established, there is evidence that its presence has a positive effect on the CoQ 10 -level. In addition it is a fact that on shortage of B 6 the glycogen metabolism is altered.
- ⁇ -ketoglutaric acid, salts and/or derivatives thereof are included in the composition. It has been found in tests carried out by the applicant that on taking ⁇ -ketoglutaric acid, salts and/or derivatives thereof, especially in combination with pyridoxine, salts of pyridoxine and/or derivatives thereof, the lactic acid concentration during hard physical labour is reduced and a positive effect on the metabolism of carbohydrates also occurs. Quite generally the tests have shown that a protective effect against free radicals is also produced. When the quantities of ⁇ -ketoglutaric acid, salts and/or derivatives thereof related B 6 are within the range 1:10 - 10:1 and in particular in the range 1:5 - 5:1 the effect is especially favorable. The absorption of the aforementioned substances in the intestine is individually conditioned, but for reaching the intended effect e.g. the following daily doses taken orally have proved appropriate:
- the daily dose is taken in the form of salts or derivatives of the substances.
- the components are available in water-soluble, dispersable and/or water-miscible form.
- complementary substances are included which participate in the rendering harmless of radicals. Examples of these are selenium, tocopherol (vitamin B), glutathione etc.
- composition of the invention can be produced by conventional blending techniques well known to those skilled in the art and requiring no further elaboration herein. In the event that hygroscopicity should prove to involve any difficulty in the blending, it is sufficient to effect the blending under anhydrous conditions as also well known to those skilled in the art .
- the most important source for incorporating CoQ 10 into the skeletal muscles is the CoQ 10 in the blood circulation.
- the concentration of CoQ 10 in the blood amounts to approx. 350-400 % of that in the skeletal muscles.
- CoQ 10 in the skeletal muscles is conditioned by the higher capacity for energy transformation, above all for combustion in the slow fibres of the skeletal muscles and their mitochondria. This has been studied earlier clinically in various patient categories, e.g. cancer patients which show signs of cardiotoxicity owing to Adriamycin R -treatment, patients with cardiomiopathies and patients with strain angina. In all these cases low, and sometimes extremely low. CoQ 10 values in the muscles coincide with far-reaching histopathological findings with inter alia rupturing of the mitochondria. The most immediate comparison with healthy test subjects can be made in respect of patients with strain angina and where mitochondria rupturings exist above all in the slow fibres and this leads inter alia to a strong impoverishment of the combustion capacity of the slow fibres.
- Test 2 Treatment of healthy, largely inactive men and women
- test After a preliminary test (control test) the test subjects were reexamined after 4 and 8 weeks treatment. Slight digressions were recorded, but these were completely randomized and were due to factors other than side-effects.
- the different treatment regimes were tolaratod well (no side-effects were noted) and did not in any way detrimentally affect the test subjects.
- the CoQ 10 concentration in the venous blood was determined in the control test and after 4 weeks of treatment. The basic values which were measured in the control test were wholly comparable between the four groups. After 4 wceks of treatment the concentration had increased for groups 3 and 4, that is to say those which were treated with CoQ 10 (in mixture - TLI - or on its own).
- the test results are evident from Figure 1 which shows the CoQ 10 content of the four test groups in the control test and on re-examinations after 4 weeks of treatment.
- the increase of the CoQ 10 of group 3 and 4 was 90 and 175, respectively.
- the absolute values in the majority were below what is regarded as the clinically therapeutically effective region ( 2-3 regarded as the clinically therapeutically effective region ( 2-3 regarded as the clinically therapeutically effective region ( 2-3 regarded as the clinically therapeutically effective region ( 2-3 regarded as the clinically therapeutically effective
- the W OBLA was not affected by anyone of the treatment regimes. It could be shown, though, that the intake of CoQ 10 did alter the W SL , that is to say the maximum working capacity. With regard to W SL it is a fact that it depends on the capacity of the muscle to carry out aerobic work as well as on the anaerobic development of energy, that is to say lactic acid formation and release of lactic acid to the extracellular space and, inter alia, the blood circulation. Experimental results showed that after 0 weeks of treatment the interrelationship between W SL and the highest lactic acid concentration in the blood measured had changed for group 3 and 4. The interrelationship is shown graphically in Fig. 2a and 2b for the two groups 3 and 4 together. Fig.
- test 3 Treatment of healthy and physically active men
- test subjects were studied. They are sportsmen with regular running training each week (up to the order of magnitude of 10-12 miles for long-distance runners forming parts of a group). The test subjects were divided into two groups and treated blindly (placebo and active treatment with TLII whose content is given below in Table 2).
- Fig. 3 illustrates the physical exercize capacity measured before and after treatment with TLII expressed as W OBLA and W OBLA per kg body weight respectively in panels A and C.
- the panels D and D indicate corrsponding values expressed in per cent of base level, that is to say in per cent of the values at time 0 (control test).
- the measured values showed and increase in the working capacity for the group which was under TLII treatment, amounting to 8 % after 8 weeks compared to 3 % for the placebo group (lefthand blocks in Fig. 4b).
- the antioxidant activity depends on substances being supplied to the muscul ature whi ch i n many connecti ons are summed up under the designation cofactors and in a more popular connection "vitamins". Many of these possess a direct activity to take charge of radicals formed whilst others reduce the possibilities of radical formation above all in case of enhanced metabolism which is the case during hard physical exercize such as training and competition. Host of these substances are supplied to the body via the nourishment and, on condition that they are qualitatively acceptable, there are grounds for assuming that no deficiency situation ought to arise. However, under training and competitive conditions (mainly on elite level) there is an obvious risk of shortage in intake and hence in the normal antioxidant function of the muscles and consequent muscular damage.
- CoQ 10 takes part in the electron transport between the citric acid and the respiratory chain but the reduced form is also very active when it comes to rendering harmless especially free oxygen radicals.
- the tests described above have shown that healthy male test subjects with varying degrees of activity have a strongly individual variation in the CoQ 10 content of the muscle as well as of the blood. Tests have shown that in the muscles the CoQ 10 content increases positively with increased physical working capacity or percentage slow muscle fibres whilst the content in respects of the blood circulation is negatively related to the working capacity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A composition intended as a diet fortification to increase the efficiency at muscle work wherein the composition includes, beside any nutrients, salts, vitamins, trace substances, flavourings, aromatics, etc., known in themselves, ubiquinone (coenzyme Q10) as the essential component.
Description
DIET FORTIFICATION
The present invention relates to a composition intended to constitute a diet fortification for the temporary and/or long-term improvement of the efficiency at muscle work of the individual who takes the diet fortification, and it relates moreover to the application of such a composition.
A great number of beverages are on the market which are intended to be taken in cases of prolonged physical exertion in order to replace above all the loss of fluid the body has suffered through perspiration. It is a further objective of these beverages to replace the glucose and the salts in blood and muscles which have been consumed and/or lost. The beverages, therefore, are aqueous solutions containing different carbohydrates. The beverages of the type mentioned here are often referred to as sports beverages.
The transformation of energy in the musculature depends not only on the suppl y of substrate for energy transfer but al so depends on the metabolic preconditions required so that optimum breakdown in the muscle fibres can be achieved. This applies especially to hard and frequently prolonged physical exercize e.g. during training and competitive activity but also in cases of temporary physical strains in skilled work or in other stress situations with pronouned muscular activity (e.g. contractures).
It is the objective of the present invention to provide a composition intended primarily for healthy, physically active persons, where the composition is apt to improve the opportunities for training and thus obviously increase the physical exercize capacity. The composition is primarily intended for active persons which have reached a very high level of training, such as long-distance runners, boxers, cyclists, swimmers, decathletes and the like. Such a high level can readily be determined by those skilled in the art of sporting using inter alia ergorneter-cycle techniques. Reference is made to literature available within this area (cf. PH Astrand: Ergometri-Konditionsprov, 1962, Folksam Skriftserie). The composition
includes ingredients which can inactivate certain harmful by-products of the metabolism. The formation of such harmful substances, e.g. free oxygen radicals, are a normal biological phenomenon, and the cell has developed a number of protective mechanisms for this purpose. Examples of these are so-called antioxidants with
"trapper"-, "quencher"- or "scavenger"-like properties; terms of English origin which figuratively describe the function.
Endurance work is characterized in that large quantities of oxygen (O2) are transported to the musculature for the purpose of being used in the combustion metabolic process, carbon dioxide (CO2) and water (H2O) being formed. Such metabolic processes involve a gradual breakdown of fats and carbohydrates so as to release chemically bonded energy. A basic requirement for endurance work, therefore, is a good supply of oxygen in the muscle fibres. The term fitness also refers to the capacity available for taking up and transporting oxygen to the working musculature. This capacity in turn determines:
1. what level of working intensity can be maintained without appreciable quantitites of lactic acid being formed in the active musculature and accumulated there, which detrimentally affects the working capacity (physical fatigue), and
2. what level of "maximum" working intensity can be maintained
(symptom-limited working capacity), which is determined by the combination: capacity for oxygen transport and. lactic acid tolerance in the working musculature.
The critical value for lactic acid formation in point 1, that is to say the OBLA-value (Onset of Blood Lactate Accumulation), corresponds to a highest work load for an individual with regard to endurance work. The maximum working capacity according to point 2 or the SL-value (Symptom Limited) signifies the "ceiling" of efficiency and provides, inter alia, information as to the maximum lactic acid
concentration in muscle and blood. Ergometer cycle and graded work, that is to say stepwise increase of intensity (20-40 W) per minute are used in the so-called OBLA/SL-test. For the OBLA and SL values respectively thus obtained the symbols WOBLA and WSL are used, and the unit here is Watt (W).
It also has been found that the periphery, that is to say the working muscles, are of great importance for the energy transformation during prolonged hard work. Thus, it can be said that, in addition to increased oxygen uptake, individuals with great endurance are characterized by a high percentage of slow muscle fibres and high capillary density. In addition such individuals possess a high activity of the enzymes which participate in the combustion process. Corresponding activities concerning lactic acid formation on the other hand are lower. As a whole this means that the combustion capacity increases whilst the lactic acid formation, and thus the fatigue-inducing factors, diminish.
For the worki ng muscles and thei r fi bres certai n substances (cofactors) are essential, and sometimes of decisive importance for optimum coupling and thereby function in the gradual breakdown. This brings about less risk of "energy leakage" and radical formation associated therewith. Cofactors have different functions in the muscle cell: they activate e.g. the enzymes which participate in the breakdown and transformation of chemically bonded energy to other forms of energy, e.g. mechanical work, via ATP and creatin phosphate. Other substances, which sometimes are summed up under the concept cofactors, also can be effective as "detoxication units" in the metabolism. The body is able to control the formation of oxygen radicals under normal conditions and the formation consequently can be handled and tolerated by the tissue in question. In cases of enhanced transformation of energy and/or metabolic stress induced by other causes, the formation of free radicals increases and there are grounds for assuming that the increase is positively accelerating with the heightened transformation of energy. When cofactors are
supplied the trained muscle, as part of the total local training effect, also has an increased capacity for handling radical formation. Shortage of cofactors in the trained musculature may lead to damages which occur first on intracellular level, frequently without any symptoms. In the damages are allowed to escalate, however, more general tissue damages ("inflammatory processes") occur, which often are associated with local irritation-pain conditions and similar symptoms which may even become disabling.
Generally, it can be said that the effect described above, of capturing and rendering harmless radicals, and especially oxygen radicals, is of fundamental importance for enhancing, temporarily as well as long-term, the efficiency of the muscles and thereby of the individual. It is particularly important that the functions which are induced by training are utilized in an optimum manner.
The present invention relates to a composition containing substances (cofactors) which contribute to a more effective transformation of energy and "detoxication" in connection with the metabolism.
The present invention especially relates to a composition primarily intended to be consumed by individuals which have reached a very high level of training, and as a further aspect the invention relates to a method of use of the composition comprising administering an effective amount of the composition for increasing the capacity at muscle work and especially the capacity of such well trained individuals.
It has been found surprisingly that by taking the composition it is possible to achieve a substantial reduction of the aforementioned problems and to achieve, moreover, an improved efficiency in connection with training/competition. The composition is intended in the first place to be used in conjunction with the supply of energy through the intake of food and/or drink. In certain applications the composition is added, therefore, to the food and/or drink which is to be taken.
The composition includes as the essential component the coenzyme Q10 (hereinafter called CoQ10) chemically known as ubiquinone. According to what has been found so far, CoQ10 has several functions:
1. In the mitochondria (combustion units of the muscle cell) it holds together the functions between the citric acid cycle and the respiratory chain (the reaction of oxygen and hydrogen ions in a redox system to form water). CoQ10 brings about not only a biochemical but also a purely physical coupling inside the mitochondria between these different functions and functional units. This causes CoQ10 to be very active in case of an excess of electrons.
2. In its reduced form (quinol form) it acts in the mitochondria structure as anantioxidant. Differently from e.g. glutathione, however, it does not enter into a "recycling system" but is broken down in the microsomes of the cell and in the liver and is extracted.
3. In the space between the cell wall and the mitochondria it facilitates the electron transport, so far as can be judged in connection with lactic acid formation. There are many indications that CoQ10 in this environment too has a "trapper"- and "scavenger"-function, analogously to that in the mitochondria.
Beside CoQ10, the composition as a rule includes nutrients, salts, vitamins, trace substances, flavourings, aromatics etc, known per se.
To enhance further the readiness and capacity of the muscles to handle prolonged and heavy exercize L-carnitine and/or pyridoxine (vitamin B6) are incorporated into the composition in accordance with an embodiment of the invention. In certain applications salts and/or derivatives of L-carnitine and/or pyridoxine arc included in the composition. Carnitine has a key function in the transport of free fatty acids into the mitochondria and in the combustion of fatty acids to carbon dioxide and water. If carnitine, and hence the
conveyor of free fatty acids is lacking, these will accumulate intracellularly in even higher concentrations. Free fatty acids have a releasing effect on the mitochondria breathing with a consequent increased radical formation. Although the role of lϊg has not been clearly established, there is evidence that its presence has a positive effect on the CoQ10-level. In addition it is a fact that on shortage of B6 the glycogen metabolism is altered.
In accordance with another embodiment of the invention α-ketoglutaric acid, salts and/or derivatives thereof are included in the composition. It has been found in tests carried out by the applicant that on taking α-ketoglutaric acid, salts and/or derivatives thereof, especially in combination with pyridoxine, salts of pyridoxine and/or derivatives thereof, the lactic acid concentration during hard physical labour is reduced and a positive effect on the metabolism of carbohydrates also occurs. Quite generally the tests have shown that a protective effect against free radicals is also produced. When the quantities of α-ketoglutaric acid, salts and/or derivatives thereof related B6 are within the range 1:10 - 10:1 and in particular in the range 1:5 - 5:1 the effect is especially favorable. The absorption of the aforementioned substances in the intestine is individually conditioned, but for reaching the intended effect e.g. the following daily doses taken orally have proved appropriate:
CoQ10 10- 700 mg preferably 10-500 mg L-carnitine 100-5000 mg " 200-3000 mg pyridoxine 10- 800 mg " 20- 500 mg
Corresponding effects are achieved if the daily dose is taken in the form of salts or derivatives of the substances.
In order to facilitate the absorption in the intestine it is preferable if the components are available in water-soluble, dispersable and/or water-miscible form.
The upper limit values given have been found to lie well below the levels which in healthy, voluntary test subjects can produce side effects in any form.
In accordance with a further preferred embodiment complementary substances are included which participate in the rendering harmless of radicals. Examples of these are selenium, tocopherol (vitamin B), glutathione etc.
The composition of the invention can be produced by conventional blending techniques well known to those skilled in the art and requiring no further elaboration herein. In the event that hygroscopicity should prove to involve any difficulty in the blending, it is sufficient to effect the blending under anhydrous conditions as also well known to those skilled in the art .
Test 1 - Description of indication
A great number of healthy, middle-aged men with varying physical exercize capacity/training volume have been examined so as to determine the normal value of CoQ10 in the blood and skeletal muscles (external thigh muscle, m. vastus lateralis). The mean value of CoQ10 in the skeletal muscle was 0.18 mg x g-1 with a variation corresponding to 0.07-036 mg per gram. The corresponding value for venous blood was 0.7 mg x ml-1. The muscle as well as the blood data for CoQ10 indicate that great individual variations exist for individuals who otherwise are clinically in good health. The lowest values in muscle and blood exist in the concentration region which is regarded as pathological in conjunction with illnesses such as cardiomyopathy or cardiotoxicity induced by medicines such as e.g. AdriamycinR.
It was possible to show that the variation in the CoQ10 content in the skeletal muscle varies jointly with the quality of the muscle expressed as the percentage of slow (LF) muscle fibres (r = 0.62, p <0.001). There was also a positive connection if the CoQ10 content of the muscle was related to the physical exercize capacity expressed as e.g. WOBLA related to the body weight (W x kg-1) (r = 0.70, p < 0.001). Individuals with a high physical exercize capacity (varies jointly with a high percentage of LF in the muscles) in accordance with the experiment thus have a clearly higher CoQ10 content in the muscles than individuals with a lower physical exercize capacity. It is also well established that the training volume varies jointly with the physical exercize capacity .
The most important source for incorporating CoQ10 into the skeletal muscles is the CoQ10 in the blood circulation. The concentration of CoQ10 in the blood amounts to approx. 350-400 % of that in the skeletal muscles. However, the CoQ10 content of the blood was found to be negatively related to the physical exercize capacity irrespectively of whether it is expressed as WOBLA or WSL in relation to the body weight (r = -0.48, p < 0.001, and r = -0.43, p < 0.01). This means that individuals with high physical working capacity/training volume and with high values of CoQ10 storage in the skeletal muscles had clearly lower blood values than individuals who were physically inactive. This relation must be taken as an expression indicating increased storage of CoQ10 with increased working capacity/training, increased "turn-over" depending on the increased metabolism and a certain limitation with regard to the supply of CoQ10 in order to maintain corresponding blood values at "normal" 1evel .
The storage of CoQ10 in the skeletal muscles is conditioned by the higher capacity for energy transformation, above all for combustion in the slow fibres of the skeletal muscles and their mitochondria. This has been studied earlier clinically in various patient categories, e.g. cancer patients which show signs of cardiotoxicity owing to AdriamycinR-treatment, patients with cardiomiopathies and patients with strain angina. In all these cases low, and sometimes
extremely low. CoQ10 values in the muscles coincide with far-reaching histopathological findings with inter alia rupturing of the mitochondria. The most immediate comparison with healthy test subjects can be made in respect of patients with strain angina and where mitochondria rupturings exist above all in the slow fibres and this leads inter alia to a strong impoverishment of the combustion capacity of the slow fibres.
To understand fully the storage of CoQ10 by the skeletal muscles in healthy test subjects the values for CoQ10 have to be related to the actual combustion capacity of the skeletal muscles either expressed as the percentage of slow fibres or as a marker for the mitochondria function, e.g. the activity in respect of citrate synthesis (CS). Whatever comparison is made, it shows that otherwise healthy test subjects with a high percentage of slow fibres show a similarly low relative storage of CoQ10 in the skeletal muscles as the group of patients with strain angina referred to above. Consequently there are grounds from a relative poi-nt of view to classify the CoQ10 content of the skeletal muscles of individuals with high physical exercize capacity/training volume as low compared with individuals with a lower degree of physical activity.
Summing up it can be said, therefore, that the CoQ10 values of the skeletal muscles increase with the exercize capacity/training volume whilst an inverse relationship exists for corresponding blood values which under certain conditions (metabolic stress situations) gives rise to deficiency situations regarding the provision of the muscles with precursors for the mitochondria function. If the CoQ10-content of the skeletal muscles was related to the simultaneous respiratory capacity or mitochondria function, the experimental results obtained also indicate that individuals with a high working capacity/training volume have lower values than individuals with a lower degree of physical activity. According to the test results otherwise healthy individuals with high working capacity/training volume run the risk of finding themselves in situations corresponding to a shortage of
CoQ10 for storage in the skeletal muscles and thus increased risk of escalating radical formation with accompanying cell damages and impaired function, a situation which is not too uncommon among the sporting elite.
Test 2 - Treatment of healthy, largely inactive men and women
In order to evaluate the tolerance, changes in working capacity and in the CoQ10-count of the blood tests were carried out with four groups (1-4) of test subjects which were treated with placebo (group 1), carnitine (group 2), diet fortification version 1 (group 3), hereinafter designated TLI (see Table below), or CoQ10 on its own in sesame oil formulation (group 4). The L-carnitine treatment amounted to 1000 mg per day and the CoQ10 treatment to 100 mg per day.
Table 1
After a preliminary test (control test) the test subjects were reexamined after 4 and 8 weeks treatment. Slight digressions were recorded, but these were completely randomized and were due to factors other than side-effects.
The different treatment regimes were tolaratod well (no side-effects were noted) and did not in any way detrimentally affect the test subjects. The CoQ10 concentration in the venous blood was determined in the control test and after 4 weeks of treatment. The
basic values which were measured in the control test were wholly comparable between the four groups. After 4 wceks of treatment the concentration had increased for groups 3 and 4, that is to say those which were treated with CoQ10 (in mixture - TLI - or on its own). The test results are evident from Figure 1 which shows the CoQ10 content of the four test groups in the control test and on re-examinations after 4 weeks of treatment. The increase of the CoQ10 of group 3 and 4 was 90 and 175, respectively. The absolute values in the majority were below what is regarded as the clinically therapeutically effective region ( 2-3 μg x ml-1).
The WOBLA was not affected by anyone of the treatment regimes. It could be shown, though, that the intake of CoQ10 did alter the WSL, that is to say the maximum working capacity. With regard to WSL it is a fact that it depends on the capacity of the muscle to carry out aerobic work as well as on the anaerobic development of energy, that is to say lactic acid formation and release of lactic acid to the extracellular space and, inter alia, the blood circulation. Experimental results showed that after 0 weeks of treatment the interrelationship between WSL and the highest lactic acid concentration in the blood measured had changed for group 3 and 4. The interrelationship is shown graphically in Fig. 2a and 2b for the two groups 3 and 4 together. Fig. 2a relating to the result before the treatment with CoQ10 (on its own) or with TLI and Fig. 2b after the treatment with CoQ10 and TLI (same daily dose CoQ10). The lactic acid concentration in the blood, BHLA, is indicated in the Figures along the X-axis (nmol x 1-1) and WSL along the Y-axis (W). It is evident from the result that after 8 weeks of treatment the interrelationship between WSL and BHLA, WSL=f(BHLA), had a steeper slope than in the control test and that the highest values of WSL were attained at higher values of BHLA than in the control test. It is clear from the result that the test subjects after treatment during 8 weeks tolerated higher values of BH LA which in turn resulted in higher values for WSL than before the treatment. Corresponding changed did not exist in groups 1 and 2 after treatment during 4 and 8 weeks, respectively.
Test 3 - Treatment of healthy and physically active men
In order to evaluate the connection between diet additives and hard systematic training, physically active test subjects were studied. They are sportsmen with regular running training each week (up to the order of magnitude of 10-12 miles for long-distance runners forming parts of a group). The test subjects were divided into two groups and treated blindly (placebo and active treatment with TLII whose content is given below in Table 2).
Table 2
Fig. 3 illustrates the physical exercize capacity measured before and after treatment with TLII expressed as WOBLA and WOBLA per kg body weight respectively in panels A and C. The panels D and D indicate corrsponding values expressed in per cent of base level, that is to say in per cent of the values at time 0 (control test).
It is evident from the test results that the physical exercize capacity expressed as WOBLA measured was higher for both groups after 4 weeks as well as after 8 weeks of treatment, 9 % and 12 %, respectively (Fig. 3A and B), but the change was significant only for the group which had been treated with TLII. The picture remained the same if the WOBLA values were related to the individual body weights. The improvement then was 8 % (4 weeks) and 12 % (8 weeks) respectively for the test group which was under active treatment. Fig. 4a and b refer to the symptom-limited working capacity, WSL. Fig. 4a indicates the absolute values at weeks 0.4 and 8 and Fig. 4b shows
the changes after 4 and 8 weeks respectively in per cent of the values in the control test (week 0), WSLO.
Regarding the symptom-limited work load ("maximum work"), the measured values showed and increase in the working capacity for the group which was under TLII treatment, amounting to 8 % after 8 weeks compared to 3 % for the placebo group (lefthand blocks in Fig. 4b).
SUMMARY AND CONCLUSIONS
In general it can be stated that a normally functioning muscle metabolism presupposes beside the normal enzymatic machinery also a capacity for taking charge of the radical formation which always occurs in connection with the metabolism of substances. The free radicals, especially the oxygen radical, would otherwise have a detrimental effect on subcellular and cellular structures which may lead to damages and inflammatory processes in the end, with an irritation/pain as part of the symptom picture. The normal muscle fibres have a number of biological systems to render harmless the radicals formed and the term antioxidants is used parallel with the English terms "trapper"-, "scavenger"- and "quencher"-function.
The antioxidant activity depends on substances being supplied to the muscul ature whi ch i n many connecti ons are summed up under the designation cofactors and in a more popular connection "vitamins". Many of these possess a direct activity to take charge of radicals formed whilst others reduce the possibilities of radical formation above all in case of enhanced metabolism which is the case during hard physical exercize such as training and competition. Host of these substances are supplied to the body via the nourishment and, on condition that they are qualitatively acceptable, there are grounds for assuming that no deficiency situation ought to arise. However, under training and competitive conditions (mainly on elite level) there is an obvious risk of shortage in intake and hence in the normal antioxidant function of the muscles and consequent muscular damage.
An important antioxidant function of this kind is performed by the coenzyme Q or CoQ10 especially in its reduced form. Normally CoQ10 takes part in the electron transport between the citric acid and the respiratory chain but the reduced form is also very active when it comes to rendering harmless especially free oxygen radicals. The tests described above have shown that healthy male test subjects with varying degrees of activity have a strongly individual variation in the CoQ10 content of the muscle as well as of the blood. Tests have shown that in the muscles the CoQ10 content increases positively with increased physical working capacity or percentage slow muscle fibres whilst the content in respects of the blood circulation is negatively related to the working capacity. If the content in the skeletal muscles is standardized in relation either to the muscle fibre composition or to a marker of the mitochondria function, values are obtained which suggest possibilities of a biological deficiency situation in the skeletal muscles, above all in physically extremely active individuals. This applies primarily to intensively competing and severely trained individuals with high physical exercize capacity expressed as fitness, that is to say the capacity of hard exercize during prolonged periods and consequently high oxygen metabolism in the skeletal muscles.
Different treatment regimes have been tested on voluntary test subjects; either physically largely inactive or trained individuals. Physically inactive individuals are affected only by CoQ10 as such or in combination with other substances (say TLI) in that the symptom-limited working capacity (WSL, "maximum" working capacity) was altered to such a degree that WSL before the treatment was not related to the maximum lactic acid concentration in the blood, but that such a positive connection existed after treatment. Those who increased their lactic acid concentration in the blood also increased their maximum working capacity. No alteration of the submaximal worki ng capaci ty e. g. WOBLA was observed i n the physi cal l y inactive test subjects.
Physically active individuals which are treated with a cofactor regime (say TLII) increased their working capacity as a result of the treatment. In tests on an ergometer cycle an increase of the submaximal working intensity, WOBLA was found and the effect of the treatment, moreover, was particularly pronounced in respect of the symptom-limited working capacity, WSL.
The voluntary test subjects reported no serious side effects from the respective treatment and the negative experiences which were reported were wholly randomized and relatively speaking wholly negligibbe.
Claims
1. A composition intended for.oral intake to be used as a diet fortification to increase the efficiency at muscle work, c h a r a c t e r i z e d in that the composition includes as the essential component ubiquinone (coenzyme Q10) possibly together with substances known per se such as nutrients, salts, vitamins, trace substances, flavorings, aromatic, etc.
2. A composition in accordance with claim 1, c h a r a c t e ri z e d in that the composition also includes L-carnitine, salts of L-carnitine and/or derivatives of L-carnitine.
3. A composition in accordance with claim 1 or 2, c h a r a c t e ri z e d in that the composition includes pyridoxine (B6), salts of pyridoxine and/or derivatives of pyridoxine.
4. A composition in accordance with anyone of claims 1-3, c h a r a c t e r i z e d in that the composition includes α-ketoglutaric acid, salts and/or derivatives thereof.
5. A composition in accordance with claim 4, c h a r a c t e ri z e d in that the α-ketoglutaric acid, salts and/or derivatives thereof are included in the composition related to vitamin B6 in a weight ratio of 1:10-10:1, preferably in a ratio of 1:5-5:1.
6. A composition in accordance with one or more of the preceding claims, c h a r a c t e r i z e d in that at least the ubiquinone present in the composition is in a water-soluble, water-dispersable and/or water-mi scible form.
7. A composition in accordance with one or more of claims 2-6, c h a r a c t e r i z e d in that the composition contains ubiquinone, salts and/or derivatives thereof in a quantity of 10-700 mg, preferably 10-500 mg, the quantity specified relating to daily intake.
8. A composition in accordance with anyone of claims 2-7, c h a r a c t e r i z e d in that the composition includes L-carnitine and pyridoxine, salts and/or derivatives thereof in the quantities 0.1-5 g and 20-800 mg respectively, preferably 0.2-3 g and 20-500 mg respectively, the quantities specified relating to daily intake.
9. A composition in accordance with one or more of the preceding claims, c h a r a c t e r i z e d in that the composition includes further substances which render harmless free radicals e.g. selenium, tocopherol (vitamin E), glutathione, vitamin A etc.
10. Use of ubiquinone (coenzyme Q10) as the essential component in diet fortification to increase the efficiency at muscle work.
11. Use in accordance with claim 10, c h a r a c t e r i z e d in that ubiquinone is present together with L-carnitine, salts and/or derivatives of L-carnitine, pyridoxine (vitamin B6) and/or salts and/or derivatives of pyridoxine.
12. Use in accordance with claim 10, c h a r a c t e r i z e d in that ubiquinone, L-carnitine and pyridoxine, salts and/or derivatives thereof are included in quantities of 10-700 mg,
0.1-5 g and 20-500 mg respectively, preferably 10-500 mg, 0.2-3 g and 20-500 mg respectively calculated on daily intake.
13. Use in accordance with anyone of claims 10-12, c h a r a c t e r i z e d in that α-ketoglutaric acid, salts and/or derivatives thereof are included related to B6 in a weight ratio of 1:10-10:1, preferably in a weight ratio of 1:5-5:1.
14. Use in accordance with one or more of claims 10-13, c h a r a c t e r i z e d in that substances which bond free radicals e.g. selenium, tocopherol (vitamin E), glutathione, vitamin A etc. are included.
15. A method of use of the composition claimed in claims 1-9 comprising administering an effective amount thereof to an individual for increasing the capacity at muscle work.
16. A method as claimed in claim 15, comprising administering said composition to an individual having reached a very high level of training for increasing the capacity of said individual.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8703321A SE8703321D0 (en) | 1987-08-27 | 1987-08-27 | KOSTFORSTERKNING |
SE8703321-3 | 1987-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989001740A1 true WO1989001740A1 (en) | 1989-03-09 |
Family
ID=20369397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1988/000436 WO1989001740A1 (en) | 1987-08-27 | 1988-08-26 | Diet fortification |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2317688A (en) |
SE (1) | SE8703321D0 (en) |
WO (1) | WO1989001740A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2230418A (en) * | 1989-03-31 | 1990-10-24 | Therapy Advisory Services Limi | Dietary supplement |
WO1998043617A3 (en) * | 1997-03-27 | 1998-12-17 | Michael J Sole | Nutritional composition for improvements in cell energetics |
US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
EP1014965A1 (en) * | 1997-06-16 | 2000-07-05 | The Regents of the University of California | Dietary compositions for enhancing metabolism and alleviating oxidative stress |
US6579866B2 (en) | 2000-12-28 | 2003-06-17 | Mccleary Larry | Composition and method for modulating nutrient partitioning |
US8703209B2 (en) | 2003-06-17 | 2014-04-22 | Edward Larry McCleary | Composition and method for modulating hydrogen ion physiology |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100459A2 (en) * | 1982-07-07 | 1984-02-15 | Eisai Co., Ltd. | An aqueous liquid containing a fat-soluble substance |
DE3405581A1 (en) * | 1983-02-16 | 1984-10-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Rom/Roma | PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY EFFECTIVENESS FOR USE IN HEART AND VESSEL THERAPY |
GB2178662A (en) * | 1985-08-06 | 1987-02-18 | Seuref Ag | Pharmaceutical compositions containing ubiquinones |
-
1987
- 1987-08-27 SE SE8703321A patent/SE8703321D0/en unknown
-
1988
- 1988-08-26 WO PCT/SE1988/000436 patent/WO1989001740A1/en unknown
- 1988-08-26 AU AU23176/88A patent/AU2317688A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100459A2 (en) * | 1982-07-07 | 1984-02-15 | Eisai Co., Ltd. | An aqueous liquid containing a fat-soluble substance |
DE3405581A1 (en) * | 1983-02-16 | 1984-10-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Rom/Roma | PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY EFFECTIVENESS FOR USE IN HEART AND VESSEL THERAPY |
GB2178662A (en) * | 1985-08-06 | 1987-02-18 | Seuref Ag | Pharmaceutical compositions containing ubiquinones |
Non-Patent Citations (2)
Title |
---|
DERWENT'S ABSTRACT NO. 87-146796/21; & JP,A,62 083 895. * |
PATENT ABSTRACTS OF JAPAN, Vol. 6, Nr. 165, C 121; & JP,A,57 079 891, publ. 1982-05-19. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2230418A (en) * | 1989-03-31 | 1990-10-24 | Therapy Advisory Services Limi | Dietary supplement |
WO1998043617A3 (en) * | 1997-03-27 | 1998-12-17 | Michael J Sole | Nutritional composition for improvements in cell energetics |
US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
EP1014965A1 (en) * | 1997-06-16 | 2000-07-05 | The Regents of the University of California | Dietary compositions for enhancing metabolism and alleviating oxidative stress |
EP1014965A4 (en) * | 1997-06-16 | 2001-12-19 | Univ California | Dietary compositions for enhancing metabolism and alleviating oxidative stress |
EP1413304A1 (en) * | 1997-06-16 | 2004-04-28 | The Regents Of The University Of California | Use of combination of carnitine and lipoic acid for restoring mitochondrial function |
US6579866B2 (en) | 2000-12-28 | 2003-06-17 | Mccleary Larry | Composition and method for modulating nutrient partitioning |
US8703209B2 (en) | 2003-06-17 | 2014-04-22 | Edward Larry McCleary | Composition and method for modulating hydrogen ion physiology |
Also Published As
Publication number | Publication date |
---|---|
SE8703321D0 (en) | 1987-08-27 |
AU2317688A (en) | 1989-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6277842B1 (en) | Dietary supplemental method for fat and weight reduction | |
Abraham et al. | Management of fibromyalgia: rationale for the use of magnesium and malic acid | |
Alessio et al. | Exercise-induced oxidative stress before and after vitamin C supplementation. | |
Epner et al. | Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction | |
EP1163904B1 (en) | Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium | |
EP0969744B1 (en) | Nutritional composition for improvements in cell energetics | |
AU685882B2 (en) | New beverage | |
Williams | Nutritional ergogenics in athletics | |
WO2001021208A1 (en) | Nutritional supplement for increased energy and stamina | |
Willis et al. | Iron deficiency: improved exercise performance within 15 hours of iron treatment in rats | |
WO1989001740A1 (en) | Diet fortification | |
US20030211133A1 (en) | Ingestible composition for enhancing athletic performance | |
Westin et al. | Circulating levels of selenium and zinc in relation to nutritional status in patients with head and neck cancer | |
US20210346327A1 (en) | Method for enhancing energy production and metabolism in cells | |
EP1555897B1 (en) | Ergogenic multivitamin-mineral energy supplement for the prevention of muscle fatigue | |
Jarvis et al. | The acute 1-week effects of the Zone diet on body composition, blood lipid levels, and performance in recreational endurance athletes | |
EP1355540B1 (en) | Food supplement with a slimming effect | |
US20200405799A1 (en) | Compositions for Creatine Supplementation in Creatine Non-Responders | |
SEITZ et al. | Ethanol toxicity and nutritional status | |
Ji et al. | Glutathione and exercise | |
Chow et al. | Arachidonic acid intestinal absorption: mechanism of transport and influence of luminal factors on absorption in vitro | |
CA2285490C (en) | Composition for improvement of cellular nutrition and mitochondrial energetics | |
Rivlin | Vitamin Defi ciencies | |
Ruden | Effects of oral creatine supplementation on performance and muscle metabolism during maximal exercise | |
US6500452B2 (en) | Energy-enhancing supplement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP NO SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |